Clinical trials: Adverse Event
Pelvic Floor Disorder, Female Pelvic Floor Dysfunction
Late Side-effects After Cervical Cancer Treatment - Prevention and Treatment
Late side-effects following gynecological cancer are predominantly symptoms from the pelvic region originating from the bowels, urinary tract, lymphatic system, genitals and musculoskeletal system.
- Conditions
- Pelvic Floor Disorder, Female Pelvic Floor Dysfunction, Female Sexual Dysfunction, Female Urinary Incontinence
- Trial name
- NCT06786091
- Testing
- Pelvic floor muscle training rehabilitation
- Where
- 2 sites in Norway
- Volunteers
- 25 people
- Sponsor
- St. Olavs Hospital
Breast Neoplasms
Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program
The aim of this study is to determine if therapeutic exercise before anticancer treatment will mitigate the onset or extent of cardiotoxicity comparing to therapeutic exercise performed during anticancer treatment.
- Trial name
- ATOPE (NCT03787966)
- Testing
- ATOPE-B, ATOPE-I
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Universidad de Granada
Japanese Encephalitis
Safety Surveillance After Immunization With IXIARO
This is an active electronic surveillance using data from the Defense Medical Surveillance System (DMSS) to detect and characterize serious, rare adverse events occurring within 42 days after vaccination with the Japanese…
- Trial name
- NCT01335412
- Testing
- Japanese Encephalitis Virus vaccine, inactivated, adsorbed
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Valneva Austria GmbH
IPF
Diarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Nintedanib
The goal of this observational study is to identify the demographic and clinical characteristics associated with the development of diarrheal adverse events in a Caucasian population with IPF undergoing treatment with nintedanib.
- Trial name
- EAD-IPF-N (NCT06714812)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Impaired Cognition, Depression/Anxiety
Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects
Despite long-term use in clinical practice, chronic treatment with efavirenz (EFV) has been associated with persistent central nervous system symptoms or mild or even asymptomatic neurocognitive impairment.
- Conditions
- Impaired Cognition, Depression/Anxiety, Poor Quality Sleep, Quality of Life
- Trial name
- SWEAR (NCT02042001)
- Testing
- Immediate switch to TDF/FTC/RPV, Switch to TDF/FTC/RPV after 24 weeks
- Where
- 5 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Azienda Ospedaliera San Gerardo di Monza
STEMI, Percutaneous Coronary Intervention
Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction
The study is an investigator-sponsored, prospective, multicenter, randomized, open-label study designed to compare efficacy and safety between bivalirudin and heparin in elderly patients with acute ST-segment elevation myocardial…
- Conditions
- STEMI, Percutaneous Coronary Intervention, Aged
- Trial name
- BEST (NCT03882775)
- Testing
- Bivalirudin, Heparin
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Vaccine Adverse Reaction, COVID-19
Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.
Background: Scarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-COV2 vaccines.
- Conditions
- Vaccine Adverse Reaction, COVID-19, Vaccine Reaction
- Trial name
- NCT05228912
- Testing
- COVID-19 Vaccines
- Where
- Mexico
- Volunteers
- 1,870 people, healthy volunteers welcome
- Sponsor
- Hospital Clinica Nova
Bronchiectasis
Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations
From the British Thoracic Guidelines1 and a PUBMED search there are no randomised controlled trials exploring optimum antibiotic duration for chest infections.
- Trial name
- BLTBrIV (NCT02047773)
- Testing
- Duration, Colomycin, Meropenem
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Edinburgh
COVID-19
COVID-19 Reactogenicity
The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine.
- Trial name
- NCT07051031
- Testing
- Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Marcel Curlin
HNSCC
WGA in Platinum-refractory HNSCC Underwent Nivolumab
To choose a subgroup who could clearly benefit from Nivolumab, we are proposing a prospective observational study. Whole-genome study (WGS) analysis will be performed on archived cancer tissues from patients who were (1)…
- Trial name
- NCT03917537
- Testing
- HNSCC patients have used Nivolumab
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Metabolic Effects, Immunosuppressive Agents
Impact of SCFA Supplementation on Metabolic Profiles in Serum and Urine of Kidney Transplant Recipients.
This is a randomized, double-blind, placebo-controlled clinical trial evaluating the impact of short-chain fatty acid (SCFA) supplementation on the serum and urinary metabolome in stable kidney transplant recipients.
- Conditions
- Metabolic Effects, Immunosuppressive Agents, Adverse Events, Imunological Effects
- Trial name
- METAKID (NCT06951581)
- Testing
- Short Chain Fatty Acid
- Where
- Slovakia
- Volunteers
- 41 people
- Sponsor
- University Hospital, Martin
Breast Cancer, Cardiac Toxicity
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00436566
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Mayo Clinic
Acute Liver Failure, Drug-Induced Liver Injury
Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure
Acute liver failure (ALF) is a serious condition in which the liver suddenly stops working, often leading to life-threatening complications.
- Trial name
- NCT06872372
- Testing
- N-Acetylcysteine (NAC) Treatment, Standard supportive care
- Where
- Pakistan
- Volunteers
- 62 people
- Sponsor
- Lahore General Hospital
Chemotherapy-induced Nausea and Vomiting, Adverse Event
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
This is a multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients receiving concomitant…
- Conditions
- Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer
- Trial name
- NCT03668639
- Testing
- Akynzeo, Dexamethasone
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Christina Ruhlmann
Syncope
Hypersensitive Troponin Performance to Identify Syncope at Risk of Serious Adverse Events in the Short Term
Syncope, a frequent reason for emergency room visits and hospitalization, is a symptom of three major etiological entities: cardiac causes, vaso-reflex causes and orthostatic hypotension.
- Trial name
- TROPOCOPE (NCT03528161)
- Testing
- Measurement of hypersensitive troponin
- Where
- France
- Volunteers
- 248 people
- Sponsor
- University Hospital, Toulouse
Metastatic Renal Cell Carcinoma
Urine Omics Predicting IO Therapy Responses in mRCC Patients
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.
- Trial name
- NCT04712305
- Testing
- No intervention required
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- National Taiwan University Hospital
Polypharmacy, Adverse Drug Reaction
Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients
The purpose of this study is to determine whether an educational intervention given towards health care providers working in primary health care centers can reduce inappropriate prescribing in the elderly patient and thus reduce…
- Trial name
- NCT01732302
- Testing
- Educational intervention
- Where
- Sweden
- Volunteers
- 69 people
- Sponsor
- Karolinska Institutet
Osteoarthritis, Arthritis, Rheumatoid
Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis…
- Trial name
- CONDOR (NCT00141102)
- Testing
- Celecoxib, Diclofenac + Omeprazole
- Where
- 194 sites in Belgium, Brazil and 30 more
- Volunteers
- 4,484 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Non-hodgkin Lymphoma
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05206357
- Testing
- Epcoritamab
- Where
- 41 sites in United States, Australia and 12 more
- Volunteers
- 17 people
- Sponsor
- Genmab